Vaccines have been one of the most effective and impactful medicines in history. Vaccines historically target exogenous pathogens outside the body associated with infectious diseases, and there are now over a dozen infectious diseases that are preventable via vaccination, from polio to the flu.
However, traditional vaccines face challenges breaking what scientists call “immune tolerance” or the “self-barrier” when targeting endogenous proteins inside the body associated with chronic diseases. The body does not like to mount an attack against itself, even though many diseases are caused by too much of something naturally produced by the body, such as cancer cells or neurotoxic proteins as aggregated beta-amyloid peptides.
UNS endobody vaccines are able to train the body to successfully break “immune tolerance” and safely and effectively produce endobodies against undesirable endogenous proteins.
Compared to traditional vaccines, their technologies enable more people (100% so far) including elderly patients with weakened immune systems across various ethnic diversities to respond more robustly and more specifically with fewer side effects.
Nextbigfuture Interviewed Lou Reese and Mei Mei Hu
Mei Mei Hu (CEO) is one of the co-founders and a member of UNS Board of Directors. She serves as the Chief Executive Officer. She is a member of the executive committee of United Biomedical, Inc. and a member of its Board of Directors, and previously served as co-CEO. During that time, she oversaw the launch of one of the first endobody vaccines in the world and the successful spin-out of three companies. Mei Mei was formerly a consultant at McKinsey & Company where she advised pharmaceutical companies on strategic, operational and organizational issues. Prior to that, Mei Mei was in the Securities group at Cravath, Swaine and Moore. Mei Mei is also co-founder of an investment and advisory group with active investments in real estate, energy and life sciences and. She holds a B.A. from University of Pennsylvania and her J.D. from Harvard Law School.
Lou Reese is one of the co-founders and a member of our Board of Directors. He currently serves as C_O of United Neuroscience. Lou co-founded an investment and advisory firm with active investments in real estate, energy, hospitality, and life sciences. His investments focus on achieving global impact in critical important areas through innovative models and approaches. He is passionate about better understanding communities and group flow. Lou loves all things vision and believes in creating environments in which we can reach our potential to be disruptive originals. He received his B.A. from University of Pennsylvania and attended Columbia Business School.
UNS has a vision of sculpting the immune systems of older people for brain health and other health conditions with a suite of endobody vaccines. This is similar to how the world currently sculpts the immune systems of all young people with a range of vaccines.
The goal is to get everyone to the level of the most healthy and those most immune to various diseases.
The Endobody vaccines are a platform for a variety of treatments against Parkinsons, Alzheimers, Tau, inflammation and can also boost regeneration.
They want to effect the ecosystem of the immune system within the body.
UNS is a private company. Their parent company is United Biomedical.
Alzheimer’s disease (AD) is the most common form of dementia, affecting more than five million people in the US alone; it’s also the sixth leading cause of deaths in the country. There are treatments available to treat the disease symptoms, but without affecting the underlying causes of the disease, they’re only a bandaid effect.
Not only is AD diminishing the lives of people affected and putting a strain on their caretakers, Alzheimer’s and other forms of dementia cost the US health care system over $259 billion in 2017, and may increase to over $1.1 trillion by 2050, according to a report by the Alzheimer’s Association. Since 2000, AD deaths have increased by 89 percent, while heart disease deaths have decreased by 14 percent.
More on UNS Science
Compared to other immunotherapies such as passive monoclonal antibodies that need to be infused into patients for the duration of treatment, their technologies enable the body to do most of the work in fighting disease, translating into a more convenient (think once 1-2x a year like a flu shot vs. monthly infusions) and more accessible treatment that is both affordable and easier to distribute for the global population. The gradual induction of endobodies by the immune system is also gentler on the body and the brain and thus has an excellent safety profile ultimately allowing for prophylactic applications.
UNS lead vaccine UB-311 is an anti-amyloid endobody vaccine for Alzheimer’s Disease currently in Phase II trials. UB-311 is fully synthetic and employs the UBITh platform technologies to target aggregated forms of beta-amyloid. UB-311 has successfully completed Phase I, demonstrating safety and tolerability, and is currently in Phase II trials. Preliminary data showed efficacy as measured in improvement or stabilization in all three cognitive tests conducted in the target sub-population.
Several inflammatory mechanisms impact nervous system cells to generate pain, autoimmune disease and other behavioral syndromes in both acute and chronic disease settings. They are developing a novel pipeline of endobody vaccines to clamp excessive elevations of specific neuropeptides and cytokines in order to treat migraine and several neuroinflammatory indications.
Neuromuscular diseases impair the functioning of muscles due to problems with the nerves and muscles in the body and include Amyotrophic lateral sclerosis (ALS). They are targeting several signaling proteins that govern tissue differentiation and growth and applying our endobody technologies to repair and regenerate injured and diseased tissues associated with these diseases.
def.: A substance produced by the body that counteracts the effects of other substances that your body produces
medical: A synthetically-induced physiological autoantibody that regulates biology
An endobody vaccine trains the body’s adaptive immune system to more efficiently and selectively produce antibodies against undesirable endogenous host proteins
Endobody targets include cancer cells, hormones, or neurotoxic proteins as aggregated beta-amyloid peptides